Group 1: Cloud Intelligence Technology - Yunzhisheng officially listed on the Hong Kong Stock Exchange on June 30, 2025, with the stock code "9678," becoming the first AGI stock in Hong Kong [2][5] - The company launched its first large language model, UniCore, based on BERT, and later developed the Shanhai model with 60 billion parameters, achieving significant performance in various evaluations [3][4] - Yunzhisheng's revenue from 2022 to 2024 was 601 million, 727 million, and 939 million CNY, with a compound annual growth rate (CAGR) of 25% [4] Group 2: Ophthalmic Biotechnology - Bokan Shiyun officially listed on the Hong Kong Stock Exchange on July 3, 2025, with the stock code "2592" [6] - The company focuses on developing differentiated drugs for major eye diseases using proprietary technology platforms [6] - Bokan Shiyun's core product CBT-001 is undergoing Phase III clinical trials in the US and China, aiming to provide non-invasive treatment for pterygium [6][7] Group 3: GPU Technology - Moore Threads submitted its prospectus for the Sci-Tech Innovation Board on June 30, 2025, focusing on self-developed GPUs for high-performance computing [8][9] - The company has achieved significant breakthroughs in GPU technology, with products nearing international advanced levels [10] - Revenue from 2022 to 2024 was 46 million, 124 million, and 438 million CNY, with a CAGR exceeding 200% [11] Group 4: Healthcare Payment Solutions - Meixin Health submitted its prospectus for the Hong Kong Stock Exchange on June 30, 2025, becoming the largest multi-payment platform in China [14][15] - The company has saved patients approximately 6.7 billion CNY in out-of-pocket expenses by the end of 2024 [14] - Revenue from 2022 to 2024 was 1.069 billion, 1.255 billion, and 2.035 billion CNY, with a gross profit margin of 31.1%, 36.8%, and 35.8% respectively [16] Group 5: Industrial Robotics - Yifei Technology submitted its prospectus for the Hong Kong Stock Exchange on June 30, 2025, focusing on industrial robots for the light industry [19][20] - The company is ranked fifth among domestic suppliers of industrial robots and related solutions in China [20] - As of June 21, 2025, Yifei Technology has over 400 million CNY in hand orders [22] Group 6: AI in Medical Imaging - Deshi Biotechnology submitted its prospectus for the Hong Kong Stock Exchange on June 29, 2025, focusing on AI in medical imaging [42] - The company's iMedImageTM model supports 19 types of medical imaging modalities, covering over 90% of clinical scenarios [43] - Revenue for 2023 and 2024 was 52.84 million and 70.35 million CNY, with gross profit margins of 71.0% and 65.5% respectively [48] Group 7: Antibody-Drug Conjugates - BlissBio Inc. submitted its prospectus for the Hong Kong Stock Exchange on June 29, 2025, focusing on next-generation ADCs for cancer treatment [50][51] - The company has four ADC candidates in clinical stages, with BB-1701 being the leading candidate for treating HER2-positive breast cancer [51][53] Group 8: Integrated Elderly Care Services - Puxiang Health submitted its prospectus for the Hong Kong Stock Exchange on June 30, 2025, focusing on integrated medical and elderly care services [55] - The company is ranked second among integrated elderly care service providers in North China by revenue [56] - Revenue from 2022 to 2024 was 255 million, 422 million, and 500 million CNY [57]

Group 1 - Suzhou Gaoxin District's company BoKangShiYun Biopharmaceutical Technology (Suzhou) Co., Ltd. was listed on the Hong Kong Stock Exchange on July 3, with an issue price of HKD 10.1 and a total fundraising amount of HKD 612 million [1] - BoKangShiYun is an innovative clinical-stage ophthalmic biotechnology company focused on developing novel and differentiated therapies, with a pipeline of 7 candidate drugs targeting major diseases of the eye [1] - The core product CBT-001, a global first for treating pterygium eye surface disease, is currently in Phase III clinical trials, while CBT-009 for treating juvenile myopia is expected to enter Phase III trials by the end of 2025 [1] Group 2 - The Gaoxin District has gathered over 1,400 enterprises related to the medical device and health industry, with a production value exceeding 50 billion and an annual growth rate of over 30% [2] - The district aims to continue fostering enterprise cultivation and listing as a key driver for high-quality development, enhancing the service system for the entire lifecycle of enterprises [2]

Core Viewpoint - The article highlights the successful IPO of Bokan Vision Pharmaceutical Co., Ltd., which is positioned to become a leader in the ophthalmic biotechnology sector with innovative drug candidates like CBT-001 and CBT-009 aimed at addressing unmet medical needs in eye diseases [3][5][9]. Company Overview - Bokan Vision is a biotechnology company focused on developing differentiated drugs for major eye diseases using proprietary technology platforms, including small molecule multi-kinase inhibitors and antibody-drug conjugates [6]. - The company has launched two key drug candidates: CBT-001 for treating pterygium and CBT-004 for treating vascularized eyelid lesions, both of which are expected to be the first of their kind globally [6][9]. IPO Details - On July 3, Bokan Vision officially listed on the Hong Kong Stock Exchange under the stock code "2592," raising approximately HKD 522 million through the issuance of 60.582 million shares, with a public offering oversubscribed by 78.78 times [3][4]. - The company attracted two cornerstone investors, raising a total of USD 22.8 million (approximately HKD 179 million) [3]. Clinical Development - CBT-001 has initiated Phase III clinical trials in the U.S. and China, with the potential to provide non-invasive treatment options for pterygium, thereby reducing the need for surgical intervention [8][9]. - CBT-009, aimed at treating myopia in adolescents, completed Phase I/II trials and is set to submit an IND application to the FDA in July 2024 [8][9]. Market Potential - The ophthalmic drug market is projected to exceed USD 10 billion in China, indicating significant growth potential in the sector [9]. - The demand for new ophthalmic drugs is increasing due to slow development progress in the field, making it a promising area for investment and innovation [9].

Group 1: CaoCao Inc. (曹操出行) - CaoCao Inc. officially listed on the Hong Kong Stock Exchange on June 25, 2025, with the stock code "2643" [3] - Established in 2015, CaoCao has become one of the largest ride-hailing platforms in China, covering 136 cities as of December 31, 2024, with 85 new cities added in 2024 [3] - The total Gross Transaction Value (GTV) for 2023 and 2024 was 12.2 billion yuan and 17 billion yuan, representing growth rates of 37.5% and 38.8% respectively [3] - In Q1 2024, CaoCao's GTV reached 4.8 billion yuan, a 54.9% increase year-on-year, with order volume growing by 51.8% [3][5] - The company operates a fleet of over 34,000 customized vehicles, making it the largest fleet in China according to Frost & Sullivan [4] - CaoCao launched an autonomous driving platform in February 2024 and plans to introduce L4-level Robotaxi models by the end of 2026 [4] Group 2: SAINT BELLA Inc. (圣贝拉) - SAINT BELLA Inc. listed on the Hong Kong Stock Exchange on June 26, 2025, with the stock code "2508" [7] - The company operates 96 high-end postpartum care centers under various brands, with significant growth in self-operated and managed centers from 2022 to 2024 [7] - SAINT BELLA is recognized as the largest postpartum care and recovery group in China and Asia, with a market share of approximately 1.2% in 2024 [7] Group 3: BoKang Vision Cloud (拨康视云) - BoKang Vision Cloud plans to list on the Hong Kong Stock Exchange on July 3, 2025, with an IPO market value of approximately 8.473 billion HKD [10] - The company focuses on developing ophthalmic biotechnologies, with two core products in clinical trials for treating pterygium and myopia [11] Group 4: Stand Robot (斯坦德机器人) - Stand Robot submitted its IPO application on June 23, 2025, aiming to become the first industrial embodiment intelligent robot stock [13] - The company is recognized as the fifth largest industrial mobile robot solution provider globally, with significant growth in overseas revenue [14] - From 2022 to 2024, Stand Robot's revenue grew from 96 million yuan to 251 million yuan, with a compound annual growth rate of 61.3% [14] Group 5: Megatech (镁伽科技) - Megatech submitted its IPO application on June 25, 2025, and is the largest domestic autonomous intelligent body supplier in China [17] - The company reported a revenue growth from 455 million yuan in 2022 to 930 million yuan in 2024, with a compound annual growth rate of 43.0% [18] Group 6: Yikong Intelligent Driving (易控智驾) - Yikong Intelligent Driving plans to list on the Hong Kong Stock Exchange on June 25, 2025, and is the largest provider of L4-level autonomous driving solutions in the mining sector [21] - The company achieved a revenue increase from 60 million yuan in 2022 to 986 million yuan in 2024, with a compound annual growth rate of 305.8% [22] Group 7: Weimai (微脉) - Weimai submitted its IPO application on June 27, 2025, focusing on AI-driven full-process management services in healthcare [24] - The company reported revenue growth from 512 million yuan in 2022 to 653 million yuan in 2024, with a gross margin increase from 17.2% to 19.9% [25] Group 8: Cloud Yinggu (云英谷) - Cloud Yinggu submitted its IPO application on June 26, 2025, and is the largest AMOLED display driver chip manufacturer in mainland China [28] - The company reported a revenue increase from 551 million yuan in 2022 to 891 million yuan in 2024 [30] Group 9: Chengtai Technology (承泰科技) - Chengtai Technology submitted its IPO application on June 23, 2025, and is the largest supplier of vehicle-mounted millimeter-wave radar in China [33] - The company achieved a revenue increase from 58 million yuan in 2022 to 348 million yuan in 2024, with a compound annual growth rate of 145.7% [33] Group 10: Siwei Zhili (四维智联) - Siwei Zhili submitted its IPO application on June 27, 2025, and is a leading provider of intelligent cockpit solutions in China [36] - The company reported revenue of 539 million yuan in 2022, with a slight decline in subsequent years [36] Group 11: Haima Cloud (海马云) - Haima Cloud submitted its IPO application on June 27, 2025, and is the largest GPUaaS provider for real-time cloud rendering in China [40] - The company reported revenue growth from 290 million yuan in 2022 to 520 million yuan in 2024, with a compound annual growth rate of 33.8% [41] Group 12: Jingze Biopharma (景泽生物) - Jingze Biopharma submitted its IPO application on June 27, 2025, focusing on reproductive and ophthalmic pharmaceuticals [44] - The company has raised 927 million yuan in funding and has a pre-IPO valuation of 3.09 billion yuan [45] Group 13: Immvira Bioscience (亦诺微医药) - Immvira Bioscience submitted its IPO application on June 25, 2025, focusing on oncolytic immunotherapy and engineered exosome therapy [47] - The company has a pre-IPO valuation of 485 million USD [48]

Group 1: Company Developments - Bolekan Vision Cloud-B has launched its IPO on the Hong Kong Stock Exchange, with approximately 60.58 million shares available for global sale at a price of HKD 10.10 per share, indicating the company's confidence in its value [1] - Stand Robot has submitted its listing application to the Hong Kong Stock Exchange, focusing on industrial intelligent mobile robot solutions, despite currently being in a loss-making position [2] - Chengtai Technology has filed its prospectus with the Hong Kong Stock Exchange, specializing in millimeter-wave radar products, with projected revenues increasing from 0.58 billion to 3.48 billion from 2022 to 2024 [4] Group 2: Financial Performance - China Wangwang reported revenues of approximately 23.51 billion for the fiscal year ending March 31, 2025, a slight decrease of 0.3% year-on-year, while profit attributable to equity holders increased by 8.6% to 4.34 billion [3]